Scancell Holdings PLC represents a strong commitment to innovative cancer immunotherapies. The company's corporate philosophy revolves around developing novel, targeted immunotherapies to treat and prevent cancer. Scancell Holdings PLC focuses on leveraging its expertise in the field of ImmunoBody® and Moditope® platforms to create breakthrough treatments that harness the power of the immune system. With a dedicated team of scientists and researchers, Scancell is driven by a vision to improve patients' lives through effective and personalized cancer treatments. This UK-based biotechnology company is at the forefront of advancing immunotherapeutic solutions and is dedicated to making a positive impact in the fight against cancer.

Scancell Holdings PLC primarily operates in the United Kingdom.

Some significant milestones achieved by Scancell Holdings PLC include the successful development of their innovative ImmunoBody® and Moditope® platforms for cancer immunotherapy. The company has made notable progress in advancing its lead product, SCIB1, through clinical trials, demonstrating promising results in the treatment of melanoma patients. In addition, Scancell has achieved important collaborations and partnerships with renowned organizations, such as Cancer Research UK and the University of Nottingham, further validating their technologies. These achievements highlight Scancell Holdings PLC's dedication to advancing cancer treatment options and building strong industry alliances.

Scancell Holdings PLC is a renowned biotechnology company specializing in the development of novel immunotherapies for the treatment of cancer. Established in 1997, Scancell has pushed the boundaries of cancer research and developed innovative platforms such as ImmunoBody® and Moditope®. The company's cutting-edge technology stimulates the body's immune system to target and eliminate cancer cells selectively. Scancell's dedication to advancing cancer treatment has earned them recognition worldwide. With an experienced team of scientists and a strong commitment to innovation, Scancell Holdings PLC continues to be at the forefront of immunotherapy development, offering hope for improved cancer therapies in the future.

The main competitors of Scancell Holdings PLC in the market include pharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, and Merck & Co. These companies are also involved in developing innovative therapies and treatments for various diseases. As a leading player in the biotechnology sector, Scancell Holdings PLC faces competition in terms of research capabilities, product development, and market presence. However, Scancell Holdings PLC distinguishes itself with its unique immuno-oncology platform and promising pipeline. Its dedication to advancing immunotherapies places the company in a competitive position within the market.

Scancell Holdings PLC is primarily active in the biopharmaceutical industry.

The business model of Scancell Holdings PLC focuses on the development and commercialization of novel immunotherapies to treat cancer. The company utilizes its ImmunoBody® and Moditope® platforms to create innovative and effective treatment options. Scancell aims to leverage its expertise in immunology and cancer biology to develop therapies that activate the patient's immune system to specifically target and destroy cancer cells. By combining these platforms with cutting-edge technologies, Scancell is committed to advancing personalized medicine and improving patient outcomes in the field of oncology.

P/E odnos Scancell Holdings iznosi -6,42.

KUV kompanije Scancell Holdings iznosi 0.

AlleAktien kvalitativni skor za Scancell Holdings je 5/10.

Prihod trenutno ne može biti izračunat za Scancell Holdings.

Dobit očekivana Scancell Holdings je -17,80 mil. GBP.

Scancell Holdings PLC is a biopharmaceutical company based in the UK that specializes in the development of cancer therapies and vaccines. The company was founded in 1997 and has since become one of the leading companies in this field.

Scancell Holdings isplaćuje dividendu od 0 GBP raspoređenu preko isplata u toku godine.

Dividenda za Scancell Holdings trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Scancell Holdings je GB00B63D3314.

WKN od Scancell Holdings je A1JZ3D.

Oznaka za praćenje akcija kompanije Scancell Holdings je SCLP.L.

U poslednjih 12 meseci, Scancell Holdings je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Scancell Holdings će verovatno isplatiti dividendu od 0 GBP.

Dividendski prinos od Scancell Holdings trenutno iznosi .

Scancell Holdings isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Scancell Holdings je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 GBP. To odgovara dividendnom prinosu od 0 %.

Scancell Holdings se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Scancell Holdings od 25. 9. 2024. u iznosu od 0 GBP, morali ste da imate akciju u depou pre Ex-dana 25. 9. 2024..

Isplata poslednje dividende izvršena je 25. 9. 2024..

U godini 2023 kompanija Scancell Holdings je isplatila 0 GBP kao dividende.

Dividende od Scancell Holdings se isplaćuju u GBP.